Skip to content
DataLookout
Menu

NCT07935941

A Phase I Study of HLX109 in Healthy Participants

StatusNot Yet Recruiting
PhasePhase 1
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 1 with changes below, 1 re-verified with no change.

  1. Study First Submitted

Endpoints

Primary

Safety: number and percentage of participants with adverse events (AEs) assessed by CTCAE v6.0
Timeframe: Up to approximately 84 days
Safety: number and percentage of participants with serious adverse events (SAEs) assessed by CTCAE v6.0
Timeframe: Up to approximately 84 days
Safety: number and percentage of participants with adverse events of special interest (AESIs) assessed by CTCAE v6.0
Timeframe: Up to approximately 84 days
Safety: number and percentage of participants with laboratory abnormalities
Timeframe: Up to approximately 84 days
Safety: number and percentage of participants with notable 12-Lead electrocardiogram (ECG) values
Timeframe: Up to approximately 84 days
Safety: number and percentage of participants with clinically notable vital signs
Timeframe: Up to approximately 84 days

Secondary (13)

PK: peak concentration (Cmax)
PK: area under the concentration-time curve (AUC0-t, AUC0-inf)
PK: time to peak concentration (Tmax)
PK: terminal elimination half-life (t1/2)
PK: apparent clearance (CL/F)
Show 8 moreShow less
PK: apparent volume of distribution (Vz/F)
PK: mean residence time (MRT)
PK: percentage of extrapolated AUC (%AUCex)
Immunogenicity: incidence of anti-drug antibody (ADA) against HLX109 and recombinant human hyaluronidase.
Immunogenicity: incidence of neutralizing antibody (NAb) against HLX109 and recombinant human hyaluronidase.
Exploratory: serum free/total soluble IL-1RAP (sIL-1RAP) levels
Exploratory: ex vivo stimulated cytokine release levels in whole peripheral blood
Exploratory: IL-1RAP receptor occupancy (RO)

Arms and interventions

HLX109Experimental

Dose Escalation

PlaceboPlacebo comparator

Dose Escalation

Drugs: HLX109, Placebo

Sites

2 sites in 2 countries

Australia 1, China 1